Milrinone versus Epinephrine in Cardiac Surgery: An Entropy-Balanced Cohort Study.
Peiris Sashi S, Peiris Thanushi T, Sin Jesselyn J, Karamesinis Alexandra A et al.
To compare clinical outcomes associated with milrinone and epinephrine use after cardiac surgery. Single-center, retrospective, entropy-balanced cohort study. Intensive care unit (ICU) of a large tertiary academic hospital in the United States, 2001-2022. Adult patients admitted to intensive care after cardiac surgery. Initial treatment with milrinone or epinephrine within 48 hours of ICU admission, classified by the agent started first. The primary outcome was 90-day mortality. Secondary outcomes included acute kidney injury, renal replacement therapy, ICU length of stay (LOS), hospital LOS, and time in postoperative organ dysfunction. Of 13,023 cardiac surgical patients, 1,310 (10%) received milrinone (312 [24%]) or epinephrine (998 [76%]) as the first agent. After entropy balancing, there was no evidence of a difference in 90-day mortality between milrinone and epinephrine groups (7.1% v 6.6%; risk ratio [RR], 1.1; 95% CI, 0.67-1.7). Milrinone was associated with longer ICU LOS (mean difference [MD], +1.8 days; 95% CI, 0.74-3.0), longer hospital LOS (MD, +1.2 days; 95% CI, 0.11-2.3), longer time in postoperative organ dysfunction (MD, +14 hours; 95% CI, 7.5-21), higher risk of acute kidney injury (73% v 61%; RR, 1.2; 95% CI, 1.1-1.3), and higher risk of renal replacement therapy (13% v 7.6%; RR, 1.7; 95% CI, 1.2-2.3). In this entropy-balanced study, there was no evidence of a difference in 90-day mortality between milrinone and epinephrine. Milrinone was associated with more complications and longer LOS, though these findings remain hypothesis-generating and warrant a randomized trial.